Cell therapy of a chronic continuous form of ulcerative colitis with severe activity with autological multipotent mesenchymal stromal cells: analysis of the clinical case
https://doi.org/10.29235/1814-6023-2020-17-4-391-400
Abstract
Ulcerative colitis is an inflammatory disease of the mucosa of the colon and rectum. The clinical practice of cell therapy programs based on mesenchymal stem cells allows to limit patient data on the use of hormonal or immunosuppressive drug therapy. The article presents a clinical case of 52 years man with ulcerative colitis, which was treated by autologous multipotent mesenchymal stromal cells that pass through the inferior mesenteric artery. Treatment control was carried out 43 days after the procedure. The following results were obtained: a decrease in the diseases activity index with a severe degree (DAI = 9) to mild (DAI = 4), refusal of steroid therapy, patient satisfaction according to SF-36 questionnaire and diary.
About the Authors
A. U. Varabei
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Aliaksandr U. Varabei – Corresponding Member, D. Sc. (Med.), Professor, Head of the Department
3/3, P. Browka Str., 220013, Minsk
M. M. Zafranskaya
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Marina M. Zafranskaya ‒ D. Sc. (Med.), Assistant Professor, Chief Researcher
3/3, P. Browka Str., 220013, Minsk
A. G. Dybau
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Aleh G. Dybau – Postgraduate student
3/3, P. Browka Str., 220013, Minsk
D. B. Nizheharodava
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Darya B. Nizheharodava – Ph. D. (Biol.), Assistant Professor, Leading Researcher
3/3, P. Browka Str., 220013, Minsk
N. A. Lahodzich
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Natallia A. Lahodzich – Ph. D. (Med.), Assistant Professor
3/3, P. Browka Str., 220013, Minsk
A. M. Starastsin
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Andrej M. Starastsin ‒ Postgraduate student
3/3, P. Browka Str., 220013, Minsk
H. Yu. Adamovich
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Hanna Yu. Adamovich – Junior Researcher
3/3, P. Browka Str., 220013, Minsk
D. Yu. Korostelev
Minsk Regional Clinical Hospital
Belarus
Belarus
Dmitry Yu. Korostelev – X-ray endovascular surgeon
1, a/g Lesnoy, Minsk Region
References
1. Ng S. C., Shi H. Y., Hamidi N., Underwood F. E., Tang W., Benchimol E. I. [et al.]. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 2017, vol. 390, no. 10114, pp. 2769–2778. https://doi.org/10.1016/s0140-6736(17)32448-0
2. Gorgun Ju. V., Borovnjova E. A., Stoljarova T. A., Jurkevich A. S., Zharskaja O. M., Vladimirova I. A., Saevich N. I. Chronic inflammatory bowel disease in the Republic of Belarus. Lechebnoye delo [Medical business], 2017, vol. 3, no. 55, pp. 5–12 (in Russian).
3. Chumanevich A. A., Chaparala A., Witalison E. E., Hossam T., Hofseth A. B., Lane C. [et al.]. Looking for the best anti-colitis medicine: a comparative analysis of current and prospective compounds. Oncotarget, 2017, vol. 8, no. 1, pp. 228–237. https://doi.org/10.18632/oncotarget.13894
4. Mahadevan U. Medical treatment of ulcerative colitis. Clinics in Colon and Rectal Surgery, 2004, vol. 17, no. 1, pp. 7–19.
5. Lazebnik L. B., Knyazev O. V., Parfenov A. I., Ruchkina I. N., Rogozina V. A., Konoplyannikov A. G. Transplantation of allogeneic mesenchymal bone marrow stem cells increases the duration of remission and reduces the risk of ulcerative colitis. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and clinical gastroenterology], 2010, vol. 3, pp. 5–10 (in Russian).
6. Shi X., Chen Q., Wang F. Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and metaanalysis of experimental and clinical studies. Stem Cell Research and Therapy, 2019, vol. 10, art. 266. https://doi.org/10.1186/s13287-019-1336-4
7. Knyazev O. V., Parfenov A. I., Ruchkina I. N., Konoplyannikov A. G., Shcherbakov P. L. Combined anti-inflammatory therapy of an acute attack of ulcerative colitis with the use of bone marrow mesenchymal stem cells. Dokazatel’naya gastroenterologiya [Evidence-based gastroenterology], 2013, vol. 2, no. 4, pp. 12–19 (in Russian).
8. Fu Z., Zhang Z., Ge H. Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentallyinduced colitis in rats by regulating Th17/Treg cell balance. American Journal of Translational Research, 2018, vol. 10, no. 1, pp. 54–66.
9. Hu J., Zhao G., Zhang L., Qiao C., Di A., Gao H., Xu H. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Experimental and Therapeutic Medicine, 2016, vol. 12, no. 5, pp. 2983–2989. https://doi.org/10.3892/etm.2016.3724
10. Knyazev O. V., Parfenov A. I., Konoplyannikov A. G., Ruchkina I. N., Churikova A. A., Bykova S. V., Albulova E. A., Boldyreva O. N., Fadeeva N. A., Lishchinskaya A. A. Safety of mesenchymal stromal cell therapy for inflammatory bowel deases: results of a 5-year follow-up. Terapevticheskii arkhiv [Therapeutic archive], 2015, vol. 87, no. 2, pp. 39–44 (in Russian).
11. Lalu M. M, Mclntyre L., Pugliese C., Fergusson D., Winston B. W., Marshall J. C., Granton J., Stewart D. J. Safety of cell therapy with mesenchymal stromal cells (Safecell): a systematic review and meta-analysis of clinical trials. PLoS ONE, 2012, vol. 7, no. 10, p. e47559. https://doi.org/10.1371/journal.pone.0047559
Review
For citations:
Varabei A.U., Zafranskaya M.M., Dybau A.G., Nizheharodava D.B., Lahodzich N.A., Starastsin A.M., Adamovich H.Yu., Korostelev D.Yu. Cell therapy of a chronic continuous form of ulcerative colitis with severe activity with autological multipotent mesenchymal stromal cells: analysis of the clinical case. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2020;17(4):391-400. (In Russ.) https://doi.org/10.29235/1814-6023-2020-17-4-391-400
Views: 667
Email this article 